Hims & Hers Shares Surge on Proposed FDA Peptide Deregulation

Shares of Hims & Hers Health, Inc. (HIMS) climbed as much as 11% in premarket trading on Thursday, continuing a strong upward trend after a 14% rally the previous session. The momentum is driven by a potential shift in how the U.S. government regulates specific medical compounds. The surge follows announcements from HHS Secretary Robert F. Kennedy Jr., who indicated that the FDA is currently seeking to remove 12 peptides from Category 2 restrictions. This regulatory adjustment would likely lower the barriers for the prescription and distribution of these substances. Peptides, which are frequently utilized in weight loss and general wellness treatments, have historically been subject to strict FDA categorization. Moving these compounds out of Category 2 is expected to streamline access and reduce the regulatory friction associated with their administration. Market participants are reacting positively to the prospect of expanded access, as such a move would likely allow telehealth providers like Hims & Hers to scale their peptide-based offerings more efficiently and reach a broader patient base.